ATE272040T1 - Durch hydroxylierung aktivierte medikamentvorstufen - Google Patents
Durch hydroxylierung aktivierte medikamentvorstufenInfo
- Publication number
- ATE272040T1 ATE272040T1 AT99901732T AT99901732T ATE272040T1 AT E272040 T1 ATE272040 T1 AT E272040T1 AT 99901732 T AT99901732 T AT 99901732T AT 99901732 T AT99901732 T AT 99901732T AT E272040 T1 ATE272040 T1 AT E272040T1
- Authority
- AT
- Austria
- Prior art keywords
- activated
- hydroxylation
- predrugs
- prodrugs
- those
- Prior art date
Links
- 230000033444 hydroxylation Effects 0.000 title abstract 2
- 238000005805 hydroxylation reaction Methods 0.000 title abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 101000725164 Homo sapiens Cytochrome P450 1B1 Proteins 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 238000007262 aromatic hydroxylation reaction Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/215—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
- C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/36—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/38—Amides of thiocarboxylic acids
- C07C327/48—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/57—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9802522.4A GB9802522D0 (en) | 1998-02-06 | 1998-02-06 | Hydroxylation activated prodrugs |
| US09/115,015 US6214886B1 (en) | 1998-02-06 | 1998-07-14 | Hydroxylation activated prodrugs |
| PCT/GB1999/000155 WO1999040056A1 (en) | 1998-02-06 | 1999-02-02 | Hydroxylation activated prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE272040T1 true ATE272040T1 (de) | 2004-08-15 |
Family
ID=26313066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99901732T ATE272040T1 (de) | 1998-02-06 | 1999-02-02 | Durch hydroxylierung aktivierte medikamentvorstufen |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US6677383B1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1051383B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4642226B2 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE272040T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2173899A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2319836C (cg-RX-API-DMAC7.html) |
| DE (1) | DE69918950T2 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2226332T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO1999040056A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69918950T2 (de) | 1998-02-06 | 2005-07-28 | De Montfort University | Durch hydroxylierung aktivierte medikamentvorstufen |
| GB2334256A (en) | 1998-02-12 | 1999-08-18 | Univ Montfort | Hydroxylation activated prodrugs |
| ATE444960T1 (de) * | 1999-12-06 | 2009-10-15 | Welichem Biotech Inc | Polyhydroxystilbene und -stilbenoxide als antipsoriasismittel und proteinkinasehemmer |
| US7321050B2 (en) | 1999-12-06 | 2008-01-22 | Welichem Biotech Inc. | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues |
| GB0007401D0 (en) | 2000-03-27 | 2000-05-17 | Cancer Res Campaign Tech | Substituted chalcones as therapeeutic compounds |
| AU2001248201B2 (en) * | 2000-04-13 | 2006-12-14 | Hsc Research And Development Limited Partnership | Compounds for modulating cell proliferation |
| US7626026B2 (en) | 2001-02-22 | 2009-12-01 | University Of Bradford | Pyrrolo-indole and pyrrolo-quinoline derivatives as prodrugs for tumour treatment |
| JP4862120B2 (ja) | 2001-02-22 | 2012-01-25 | ユニヴァーシティ オブ ブラッドフォード | 腫瘍治療のためのプロドラッグとしてのベンズ−インドールおよびベンゾ−キノリン誘導体 |
| US6589997B2 (en) * | 2001-06-29 | 2003-07-08 | North Shore-Long Island Jewish Health System | Small-molecule modulators of hepatocyte growth factor/scatter factor activities |
| GB0123780D0 (en) | 2001-10-03 | 2001-11-21 | Cancer Res Ventures Ltd | Substituted chalcones as therapeutic agents |
| GB0123777D0 (en) | 2001-10-03 | 2001-11-21 | Cancer Res Ventures Ltd | Substituted chalcones as therapeutic agents |
| US6919324B2 (en) * | 2001-10-26 | 2005-07-19 | Oxigene, Inc. | Functionalized stilbene derivatives as improved vascular targeting agents |
| GB0126889D0 (en) * | 2001-11-08 | 2002-01-02 | Paterson Inst For Cancer Res | Compounds and their uses |
| AU2003250701A1 (en) * | 2002-07-31 | 2004-02-16 | Wayne R. Danter | Protein tyrosine kinase inhibitors |
| CA2542007C (en) * | 2002-10-09 | 2010-06-29 | Wayne R. Danter | Protein tyrosine kinase inhibitors |
| MXPA05008298A (es) * | 2003-02-04 | 2005-09-20 | Yakult Honsha Kk | Inhibidor de la proteina de resistencia a cancer de mama. |
| WO2005092904A1 (en) * | 2004-03-26 | 2005-10-06 | Hsc Research And Development Limited Partnership | Novel compounds for modulating cell proliferation |
| AU2006232435B8 (en) | 2005-03-30 | 2011-09-15 | Kabushiki Kaisha Yakult Honsha | BCRP/ABCG2 inhibitor |
| WO2008083491A1 (en) | 2007-01-11 | 2008-07-17 | Critical Outcome Technologies Inc. | Compounds and method for treatment of cancer |
| US7784455B1 (en) * | 2007-09-18 | 2010-08-31 | Chong Carlton Le Loong | Reusable pellet shooting grenade |
| US8466151B2 (en) * | 2007-12-26 | 2013-06-18 | Critical Outcome Technologies, Inc. | Compounds and method for treatment of cancer |
| GB0803071D0 (en) * | 2008-02-20 | 2008-03-26 | Care Technologies Inc | Cancer detection methods and techniques |
| EP3023426A1 (en) * | 2008-07-17 | 2016-05-25 | Critical Outcome Technologies, Inc. | Thiosemicarbazone inhibitor compounds and cancer treatment methods |
| GB0907551D0 (en) | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
| WO2011120153A1 (en) | 2010-04-01 | 2011-10-06 | Critical Outcome Technologies Inc. | Compounds and method for treatment of hiv |
| KR20200118827A (ko) | 2018-02-02 | 2020-10-16 | 마베릭스 온콜로지, 잉크. | 젬시타빈 모노포스페이트의 소분자 약물 컨쥬게이트 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6176433A (ja) * | 1984-09-21 | 1986-04-18 | Toyobo Co Ltd | 新規なカルコン誘導体 |
| US5773435A (en) | 1987-08-04 | 1998-06-30 | Bristol-Myers Squibb Company | Prodrugs for β-lactamase and uses thereof |
| AU632992B2 (en) * | 1987-12-24 | 1993-01-21 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Pharmaceutical compositions comprising benzylidene- and cinnamylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells, certain such novel compounds and their preparation |
| US5287386A (en) | 1991-03-27 | 1994-02-15 | Thinking Machines Corporation | Differential driver/receiver circuit |
| US5430062A (en) * | 1992-05-21 | 1995-07-04 | Research Corporation Technologies, Inc. | Stilbene derivatives as anticancer agents |
| DE4236237A1 (de) | 1992-10-27 | 1994-04-28 | Behringwerke Ag | Prodrugs, ihre Herstellung und Verwendung als Arzneimittel |
| DE4309344A1 (de) | 1993-03-23 | 1994-09-29 | Gerhard Prof Dr Eisenbrand | Antineoplastische Mittel mit verstärkter Wirksamkeit |
| US5276058A (en) * | 1993-06-09 | 1994-01-04 | Nippon Hypox Laboratories Incorporated | 3,4-dihydroxychalcone derivatives |
| EP0647450A1 (en) | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Improved prodrugs for enzyme mediated activation |
| FR2710798B1 (fr) | 1993-09-27 | 1995-11-10 | Alcatel Mobile Comm France | Chaîne d'amplification en mode de courant, amplificateur opérationnel, cellule de gain et élément d'amplification correspondants. |
| JPH08188546A (ja) * | 1995-01-04 | 1996-07-23 | Kyowa Hakko Kogyo Co Ltd | カルコン誘導体 |
| GB9519490D0 (en) | 1995-09-25 | 1995-11-29 | Melvin William T | Use of a cytochrome P450 enzyme in tumour cells as a marker and target |
| US5966032A (en) | 1996-09-27 | 1999-10-12 | Northern Telecom Limited | BiCMOS transceiver (driver and receiver) for gigahertz operation |
| GB9802522D0 (en) | 1998-02-06 | 1998-04-01 | Montford University De | Hydroxylation activated prodrugs |
| DE69918950T2 (de) | 1998-02-06 | 2005-07-28 | De Montfort University | Durch hydroxylierung aktivierte medikamentvorstufen |
| GB2334256A (en) | 1998-02-12 | 1999-08-18 | Univ Montfort | Hydroxylation activated prodrugs |
| CA2319837C (en) | 1998-02-12 | 2009-10-27 | De Montfort University | Hydroxylation activated drug release |
-
1999
- 1999-02-02 DE DE69918950T patent/DE69918950T2/de not_active Expired - Lifetime
- 1999-02-02 CA CA2319836A patent/CA2319836C/en not_active Expired - Fee Related
- 1999-02-02 AT AT99901732T patent/ATE272040T1/de active
- 1999-02-02 EP EP99901732A patent/EP1051383B1/en not_active Expired - Lifetime
- 1999-02-02 WO PCT/GB1999/000155 patent/WO1999040056A1/en not_active Ceased
- 1999-02-02 AU AU21738/99A patent/AU2173899A/en not_active Abandoned
- 1999-02-02 JP JP2000530488A patent/JP4642226B2/ja not_active Expired - Fee Related
- 1999-02-02 ES ES99901732T patent/ES2226332T3/es not_active Expired - Lifetime
-
2000
- 2000-08-07 US US09/633,699 patent/US6677383B1/en not_active Expired - Lifetime
-
2001
- 2001-01-19 US US09/765,861 patent/US6346550B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU2173899A (en) | 1999-08-23 |
| JP2002502836A (ja) | 2002-01-29 |
| US6677383B1 (en) | 2004-01-13 |
| JP4642226B2 (ja) | 2011-03-02 |
| EP1051383A1 (en) | 2000-11-15 |
| EP1051383B1 (en) | 2004-07-28 |
| DE69918950D1 (de) | 2004-09-02 |
| US6346550B2 (en) | 2002-02-12 |
| ES2226332T3 (es) | 2005-03-16 |
| CA2319836C (en) | 2010-11-23 |
| US20010021717A1 (en) | 2001-09-13 |
| CA2319836A1 (en) | 1999-08-12 |
| DE69918950T2 (de) | 2005-07-28 |
| WO1999040056A1 (en) | 1999-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69918950D1 (de) | Durch hydroxylierung aktivierte medikamentvorstufen | |
| BG104780A (en) | Inhibitors of phospholipase enzymes | |
| MXPA02002901A (es) | Enzimas de ruta de enfocado lisosomal. | |
| WO2001097829A3 (en) | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases | |
| DK1141335T3 (da) | Kemisk modificerede enzymer med multipelt ladede varianter | |
| WO2004037159A3 (en) | Compounds, compositions and methods for modulating fat metabolism | |
| AU2002327180A1 (en) | Detection and therapy of vulnerable plaque with photodynamic compounds | |
| IL124593A0 (en) | Substituted aryl or heteroarylamides having retinoid-like biological activity | |
| EP1818396A3 (en) | Alpha-Amylase variants | |
| ZA991975B (en) | Enzyme inhibitors. | |
| ATE243520T1 (de) | Durch hydroxylierung aktivierte wirkstofffreigabe | |
| WO2004020458A3 (en) | Assays and compositions for identifying agents that modulate the activity of deubiquitinating agents | |
| TR199902751T2 (xx) | Proteaz inhibit�rleri. | |
| WO2006063055A3 (en) | Enzyme conjugates for use as detoxifying agents | |
| HK1039449A1 (zh) | 治疗多发性硬化的方法 | |
| SE0202705D0 (en) | Supported Disc | |
| PT1435991E (pt) | Utilização de aplidina para o tratamento de cancro pancreático | |
| AU2487602A (en) | Isolated luciferases and the use thereof | |
| WO2003087054A3 (en) | Methods for identifying compounds that modulate enzymatic activity | |
| DK1095032T3 (da) | Hidtil ukendte fluorescerende CYP2D-assayreagenser | |
| AU1719497A (en) | An enzyme with pectin esterase activity | |
| ATE493106T1 (de) | Oberflächenbehandlungsmittel für dentales hartgewebe | |
| WO2002057408A8 (en) | Chitinases, derived from carnivorous plants polynucleotide sequences encoding thereof, and methods of isolating and using same | |
| MXPA03001986A (es) | Composiciones antitromboticas. | |
| AU2001238407A1 (en) | Esterase enzymes having selective activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1051383 Country of ref document: EP |